Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Expedia Group Inc (EXPE) Price & Performance

BioNano Genomics IncTrade
Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Expedia Group Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Expedia Group Inc trades at $322.71 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 2820.6× BioNano Genomics Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOEXPE
Market Cap
$13.66M$38.53B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$321.07
52-Week Low
$1.06$188.51
Enterprise Value
$16.26M$37.09B
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.

The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.

Expedia Group Inc

Expedia Group (EXPE) trades at $321.5, up 2.39% today, with strong technical momentum and a bullish moving average crossover. The company reported robust Q2 2026 earnings, beating estimates with EPS of $5.76 versus $5.22 expected, driven by 14% revenue growth and record adjusted EBITDA of $1.1 billion (Business Wire, 2026-08-05). Fundamentals show high profitability with a 90.43% gross margin and improving net income, while valuation ratios like P/E of 20.19 and P/S of 2.59 reflect market confidence.

Outlook is positive with raised full-year revenue guidance to $16.05B-$16.22B (WSJ, 2026-08-05), supported by AI and B2B growth. Risks include competitive pressures and economic sensitivity. Analysts are mixed but lean bullish with a $322.95 consensus target, near the current price, suggesting limited upside but stability.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE